NEW YORK (GenomeWeb News) – Singapore-based VolitionRx today announced it has raised about $1.2 million, which will be used to support further development of its diagnostic test kits.

The firm, which is developing blood-based diagnostic tests for cancer using its nucleosomes technology, raised about $1 million through a private placement of 582,510 shares for $1.75 per share. Each share entitles the holder to one share of common stock and one warrant to purchase half a share of common stock at $2.60 per share, valid for four years.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genomic analysis of high-grade serous ovarian cancer, and more.

The new Riken president outlines some of his plans for the institute.

The Guardian discusses whether big science projects are worth the loss of resources available for other scientific pursuits.

An NEJM update from the ClinVar team highlights the difficulties of interpreting genetic variants.